Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(4): 425-433
Xiong Yan, Ye Qifa, Kong Fanhua, et al. Diagnostic criteria and research progress on Banff classification of allograft pathology in composite tissue allotransplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 425-433. doi: 10.3969/j.issn.1674-7445.2022.04.003
Citation: Xiong Yan, Ye Qifa, Kong Fanhua, et al. Diagnostic criteria and research progress on Banff classification of allograft pathology in composite tissue allotransplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 425-433. doi: 10.3969/j.issn.1674-7445.2022.04.003
shu

Diagnostic criteria and research progress on Banff classification of allograft pathology in composite tissue allotransplantation

doi: 10.3969/j.issn.1674-7445.2022.04.003

  • Institute of Hepatobiliary Diseases, Zhongnan Hospital of Wuhan University, National Quality Management and Control Center for Human Donated Organ Procurement, Transplantation Medical Center of Wuhan University, Key Laboratory of Transplantation Technology of Hubei Province, Wuhan 430071, China

More Information
    Abstract
  • Composite tissue allotransplantation (CTA) is a novel transplantation discipline to treat functional tissue or limb defects. Since a majority of CTA grafts were vascularized grafts, it is also known as vascularized composite allotransplantation (VCA). The grafts of CTA/VCA consist of two or more types of allogeneic skin, subcutaneous tissue, bone, muscle, nerve and vessel, etc. Most of CTA/VCA grafts contain skin tissues, which possess the highest antigenicity. Acute rejection after transplantation is the primary obstacle leading to CTA/VCA graft failure and primary graft dysfunction. Hence, histopathological characteristics of skin rejection in CTA/VCA grafts have become the primary hotspot. In this article, pathological features of CTA/VCA rejection, Banff classification in 2007 and related research progress were reviewed, aiming to provide reference for the diagnosis and treatment of rejection and other complications of CTA/VCA.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    ISKE J, NIAN Y, MAENOSONO R, et al. Composite tissue allotransplantation: opportunities and challenges[J]. Cell Mol Immunol, 2019, 16(4): 343-349. DOI: 10.1038/s41423-019-0215-3.
    [2]
    OZKAN O, ERTOSUN MG, OZKAN O. Technical, immunological, and ethical similarities and differences between vascularized composite allotransplantation and solid organ transplantation in current practice[J]. Transplant Proc, 2018, 50(10): 3775-3782. DOI: 10.1016/j.transproceed.2018.06.012.
    [3]
    LELLOUCH AG, TAVEAU CB, ANDREWS AR, et al. Local FK506 implants in non-human primates to prevent early acute rejection in vascularized composite allografts[J]. Ann Transl Med, 2021, 9(13): 1070. DOI: 10.21037/atm-21-313.
    [4]
    HERNANDEZ JA, MILLER J, OLECK NC, et al. OPTN/SRTR 2020 annual data report: VCA[J]. Am J Transplant, 2022, 22 (Suppl 2): 623-647. DOI: 10.1111/ajt.16980.
    [5]
    GEOGHEGAN L, AL-KHALIL M, SCARBOROUGH A, et al. Pre-transplant management and sensitisation in vascularised composite allotransplantation: a systematic review[J]. J Plast Reconstr Aesthet Surg, 2020, 73(9): 1593-1603. DOI: 10.1016/j.bjps.2020.05.010.
    [6]
    CENDALES LC, KANITAKIS J, SCHNEEBERGER S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology[J]. Am J Transplant, 2008, 8(7): 1396-1400. DOI: 10.1111/j.1600-6143.2008.02243.x.
    [7]
    MENDENHALL SD, BROWN S, BEN-AMOTZ O, et al. Building a hand and upper extremity transplantation program: lessons learned from the first 20 years of vascularized composite allotransplantation[J]. Hand (N Y), 2020, 15(2): 224-233. DOI: 10.1177/1558944718790579.
    [8]
    KAUFMAN CL, KANITAKIS J, WEISSENBACHER A, et al. Defining chronic rejection in vascularized composite allotransplantation-the American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper research goals in defining chronic rejection in vascularized composite allotransplantation[J]. SAGE Open Med, 2020, 8: 2050312120940421. DOI: 10.1177/2050312120940421.
    [9]
    MATAR AJ, CREPEAU RL, MUNDINGER GS, et al. Large animal models of vascularized composite allotransplantation: a review of immune strategies to improve allograft outcomes[J]. Front Immunol, 2021, 12: 664577. DOI: 10.3389/fimmu.2021.664577.
    [10]
    CONRAD A, PETRUZZO P, KANITAKIS J, et al. Infections after upper extremity allotransplantation: a worldwide population cohort study, 1998-2017[J]. Transpl In, 2019, 32(7): 693-701. DOI: 10.1111/tri.13399.
    [11]
    KANITAKIS J. The challenge of dermatopathological diagnosis of composite tissue allograft rejection: a review[J]. J Cutan Pathol, 2008, 35(8): 738-744. DOI: 10.1111/j.1600-0560.2007.00889.x.
    [12]
    SIKORSKA D, KAMIŃSKA D, CATAR R, et al. Non-HLA antibodies in hand transplant recipients are connected to multiple acute rejection episodes and endothelial activation[J]. J Clin Med, 2022, 11(3): 833. DOI: 10.3390/jcm11030833.
    [13]
    ANGGELIA MR, CHENG HY, CHUANG WY, et al. Unraveling the crucial roles of FoxP3+ regulatory T cells in vascularized composite allograft tolerance induction and maintenance[J]. Transplantation, 2021, 105(6): 1238-1249. DOI: 10.1097/TP.0000000000003509.
    [14]
    MESSNER F, FISCHER AC, RUNGGALDIER E, et al. Mechanical irritation in vascularized composite tissue allotransplantation triggers localized skin rejection[J]. Transplantation, 2020, 104(5): 956-969. DOI: 10.1097/TP.0000000000003075.
    [15]
    CHANDRAKER A, ARSCOTT R, MURPHY GF, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant[J]. Am J Transplant, 2014, 14(6): 1446-1452. DOI: 10.1111/ajt.12715.
    [16]
    UNADKAT JV, SCHNEEBERGER S, GOLDBACH C, et al. Investigation of antibody-mediated rejection in composite tissue allotransplantation in a rat limb transplant model[J]. Transplant Proc, 2009, 41(2): 542-545. DOI: 10.1016/j.transproceed.2009.01.024.
    [17]
    KANITAKIS J, MCGREGOR B, BADET L, et al. Absence of C4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study[J]. Transplantation, 2007, 84(2): 265-267. DOI: 10.1097/01.tp.0000266899.93315.52.
    [18]
    MORELON E, KANITAKIS J, PETRUZZO P. Immunological issues in clinical composite tissue allotransplantation: where do we stand today?[J]. Transplantation, 2012, 93(9): 855-859. DOI: 10.1097/TP.0b013e31824728b8.
    [19]
    MENGEL M, SIS B, HAAS M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection[J]. Am J Transplant, 2012, 12(3): 563-570. DOI: 10.1111/j.1600-6143.2011.03926.x.
    [20]
    PETRUZZO P, KANITAKIS J, BADET L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients[J]. Am J Transplant, 2011, 11(4): 808-816. DOI: 10.1111/j.1600-6143.2011.03469.x.
    [21]
    LODHI SA, LAMB KE, MEIER-KRIESCHE HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success[J]. Am J Transplant, 2011, 11(6): 1226-1235. DOI: 10.1111/j.1600-6143.2011.03539.x.
    [22]
    KOLLAR B, KAMAT P, KLEIN HJ, et al. The significance of vascular alterations in acute and chronic rejection for vascularized composite allotransplantation[J]. J Vasc Res, 2019, 56(4): 163-180. DOI: 10.1159/000500958.
    [23]
    DIEP GK, BERMAN ZP, ALFONSO AR, et al. The 2020 facial transplantation update: a 15-year compendium[J]. Plast Reconstr Surg Glob Open, 2021, 9(5): e3586. DOI: 10.1097/GOX.0000000000003586.
    [24]
    HEWITT CW, RAMSAMOOJ R, PATEL MP, et al. Development of stable mixed T cell chimerism and transplantation tolerance without immune modulation in recipients of vascularized bone marrow allografts[J]. Transplantation, 1990, 50(5): 766-772. DOI: 10.1097/00007890-199011000-00006.
    [25]
    BROUHA PC, PEREZ-ABADIA G, FRANCOIS CG, et al. Lymphadenectomy prior to rat hind limb allotransplantation prevents graft-versus-host disease in chimeric hosts[J]. Transpl Int, 2004, 17(7): 341-350. DOI: 10.1007/s00147-004-0724-5.
    [26]
    GRANGER DK, BRIEDENBACH WC, PIDWELL DJ, et al. Lack of donor hyporesponsiveness and donor chimerism after clinical transplantation of the hand[J]. Transplantation, 2002, 74(11): 1624-1630. DOI: 10.1097/00007890-200212150-00022.
    [27]
    SHULMAN HM, KLEINER D, LEE SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅱ. Pathology Working Group report[J]. Biol Blood Marrow Transplant, 2006, 12(1): 31-47. DOI: 10.1016/j.bbmt.2005.10.023.
    [28]
    STEINBRINK JM, WOLFE CR. Infectious complications of vascularized composite allograft transplantation[J]. Curr Opin Organ Transplant, 2020, 25(4): 377-382. DOI: 10.1097/MOT.0000000000000780.
    [29]
    KAUKE-NAVARRO M, PANAYI AC, FORMICA R, et al. Cytomegalovirus-related complications and management in facial vascularized composite allotransplantation: an international multicenter retrospective cohort study[J]. Transplantation, 2022, DOI: 10.1097/TP.0000000000004132[Epub ahead of print].
    [30]
    TCHILOEMBA B, KAUKE M, HAUG V, et al. Long-term outcomes after facial allotransplantation: systematic review of the literature[J]. Transplantation, 2021, 105(8): 1869-1880. DOI: 10.1097/TP.0000000000003513.
    [31]
    ROY SF, KRISHNAN V, TRINH VQ, et al. Lymphocytic vasculitis associated with mild rejection in a vascularized composite allograft recipient: a clinicopathological study[J]. Transplantation, 2020, 104(7): e208-e213. DOI: 10.1097/TP.0000000000003241.
    [32]
    FULLERTON ZH, TSANGARIS E, DEVRIES CEE, et al. Patient-reported outcomes measures used in facial vascularized composite allotransplantation: a systematic literature review[J]. J Plast Reconstr Aesthet Surg, 2022, 75(1): 33-44. DOI: 10.1016/j.bjps.2021.09.002.
    [33]
    LASSUS P, LINDFORD A, VUOLA J, et al. The Helsinki face transplantation: surgical aspects and 1-year outcome[J]. J Plast Reconstr Aesthet Surg, 2018, 71(2): 132-139. DOI: 10.1016/j.bjps.2017.10.007.
    [34]
    GOVSHIEVICH A, SALEH E, BOGHOSSIAN E, et al. Face transplant: current update and first Canadian experience[J]. Plast Reconstr Surg, 2021, 147(5): 1177-1188. DOI: 10.1097/PRS.0000000000007890.
    [35]
    SHOKRI T, SAADI R, WANG W, et al. Facial transplantation: complications, outcomes, and long-term management strategies[J]. Semin Plast Surg, 2020, 34(4): 245-253. DOI: 10.1055/s-0040-1721760.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (534) PDF downloads(101) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return